Niemann-Pick Disease Type C Treatment Market Report 2026

The niemann-pick disease type c treatment market size has grown strongly in recent years. It will grow from $2.92 billion in 2025 to $3.19 billion in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to rare disease awareness initiatives, limited but established pharmacological therapies, historical underdiagnosis of NPC, regulatory incentives for orphan drugs, growth of specialty treatment centers.

The niemann-pick disease type c treatment market size is expected to see strong growth in the next few years. It will grow to $4.46 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to advancements in gene therapy research, increasing investments in rare disease R&D, improved diagnostic technologies, expanding newborn screening programs, supportive regulatory frameworks for novel therapies. Major trends in the forecast period include increased adoption of orphan drug development, rising focus on early diagnosis and screening, expansion of supportive and symptom management therapies, growing clinical trial activity for rare diseases, improved patient access programs and reimbursement support.

The rising prevalence of Alzheimer’s disease is expected to drive the growth of the Niemann-Pick disease type C (NPC) treatments market in the coming years. Alzheimer’s disease is a progressive neurodegenerative disorder marked by the buildup of beta-amyloid plaques and tau protein tangles in the brain, leading to cognitive decline, memory loss, and impairment in daily functioning, ultimately resulting in severe dementia. The increasing incidence of Alzheimer’s is primarily driven by an aging global population, as advancing age is the strongest known risk factor for the disease. NPC treatments contribute to Alzheimer’s research by providing insights into lysosomal storage disorders and lipid metabolism dysfunction. For example, in May 2024, according to the Alzheimer’s Society, a UK-based voluntary health organization, approximately 982,000 people in the UK were living with dementia, though over one-third remain undiagnosed, with the total number projected to reach 1.4 million by 2040. Therefore, the growing prevalence of Alzheimer’s disease is supporting the expansion of the Niemann-Pick disease type C treatments market.

Major companies in the NPC treatment market are focusing on the development of innovative therapies, such as neuroprotective treatments, to slow disease progression and enhance patient outcomes. Neuroprotective therapies are designed to protect the brain and nervous system from damage or degeneration, aiming to preserve neurological function in conditions like neurodegenerative diseases. For instance, in September 2024, IntraBio Inc., a U.S.-based biopharmaceutical company, received approval from the United States Food and Drug Administration (FDA) for AQNEURSA (levacetylleucine), the first stand-alone therapy for Niemann-Pick Disease Type C. This approval followed positive Phase III trial results demonstrating significant neurological improvements in NPC patients within 12 weeks. AQNEURSA provides a long-awaited treatment option for individuals affected by this rare lysosomal storage disorder, which impacts movement, cognition, and daily functioning. IntraBio also plans to explore AQNEURSA’s potential applications for other neurodegenerative and neurodevelopmental conditions.

In December 2023, Cyclo Therapeutics, Inc., a U.S.-based biotechnology company, merged with Applied Molecular Transport Inc. for $10.2 million. This merger aims to strengthen Cyclo Therapeutics’ financial and strategic position by leveraging additional resources, extending its cash runway, and advancing the clinical development and regulatory approval of Trappsol Cyclo, a potential therapy for Niemann-Pick Disease Type C1 (NPC1), through the pivotal Phase 3 global study (TransportNPC). Applied Molecular Transport Inc. is a U.S.-based clinical-stage biopharmaceutical company.

Major companies operating in the niemann-pick disease type c treatment market are Mayo Clinic, Boston Children’s Hospital, Cincinnati Children’s Hospital Medical Center, Mallinckrodt Pharmaceuticals, Rainbow Children’s Hospital, CENTOGENE N.V., The Florey Institute of Neuroscience and Mental Health, National Organization for Rare Disorders NORD, National Niemann‑Pick Disease Foundation NNPDF, Bloomsbury Genetic Therapies Ltd., Vtesse Inc., Cyclo Therapeutics Inc., Orphazyme A S, Intrabio Inc., Sarepta Therapeutics Inc., StrideBio, Azafaros B V, ViroMed, NeuroSense Therapeutics, ArmaGen, Synlogic, Editas Medicine, Passage Bio, Chameleon Bio, Aro Bio, Glycomine, Scenic Biotech, Actio Biosciences, AIRNA Therapeutics.

North America was the largest region in the niemann-pick disease type C treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the niemann-pick disease type c treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the niemann-pick disease type c treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the niemann-pick disease type c treatment market by increasing the cost of imported active pharmaceutical ingredients, biologics, and specialized manufacturing equipment used in advanced therapies. These effects are most visible in pharmacological treatment, gene therapy, and enzyme replacement therapy segments, with regions reliant on cross-border pharmaceutical supply chains such as europe and asia-pacific being more affected. Hospitals and research institutes experience higher procurement costs, which may slow treatment accessibility. However, tariffs have also encouraged localized manufacturing, regional clinical development, and strategic partnerships, supporting long-term supply stability and innovation.

The niemann-pick disease type c treatment market research report is one of a series of new reports that provides niemann-pick disease type c treatment market statistics, including niemann-pick disease type c treatment industry global market size, regional shares, competitors with a niemann-pick disease type c treatment market share, detailed niemann-pick disease type c treatment market segments, market trends and opportunities, and any further data you may need to thrive in the niemann-pick disease type c treatment industry. This niemann-pick disease type c treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Niemann-Pick disease type C (NPC) treatment refers to medical strategies aimed at managing and slowing the progression of Niemann-Pick disease type C, a rare inherited neurodegenerative disorder that impairs the body’s ability to metabolize cholesterol and other lipids within cells. These treatments include pharmacological and supportive therapies designed to reduce neurological symptoms, stabilize disease progression, and enhance quality of life.

The primary disease types in Niemann-Pick disease type C treatment are Niemann-Pick disease type C1 and Niemann-Pick disease type C2. Niemann-Pick disease type C1 (NPC1) is a rare, progressive, and fatal lysosomal storage disorder caused by mutations in the NPC1 gene, resulting in defective intracellular cholesterol trafficking, lipid accumulation in lysosomes, and severe neurological decline, including cognitive impairment, motor dysfunction, and organ damage. This disorder affects various age groups, including infantile, juvenile, and adult patients, and its treatments are utilized by hospitals, specialty clinics, and research and academic institutions.

The niemann-Pick disease type C treatment market includes revenues earned by entities through medication management, symptom management, neurological care, liver care, and genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.